Artificial intelligence advances in drug development

Leonard Lee, head of growth and customer success for Accelerated Discovery at IBM, discusses the ways AI is transforming drug discovery and assisting scientists today.

The potential of companies developing artificial intelligence (AI)-based tools for drug discovery and development has driven investment and deals with major biopharma companies, but challenges for AI biotechs and biopharma companies are emerging as the field moves beyond the hype towards impact.

POLARIS^qb is slashing the timeframes and costs of drug discovery by using the unique processing power of quantum technology to identify the best lead compounds for drug development.

Biovista combines augmented and artificial intelligence to drive new possibilities for safer, more-precise medicines.

By integrating artificial intelligence, three-dimensional and multi-organ technology, Quris-AI is developing a ground-breaking clinical-prediction platform with the potential to revolutionize disease modelling and personalized medicine.

Enveda Biosciences combines machine learning and complex naturally-based libraries of compounds to find potential hits and leads for previously undruggable targets and to uncover novel mechanisms of action.

Perspix Biotech’s roPROTix platform combines artificial intelligence, robotics, and wet biology in a closed-loop feedback system for the discovery of next-generation multi-targeting biological therapeutics.

Taking an innovative approach to applying artificial intelligence (AI) to medical imaging, Quibim is designing predictive panels to enable healthcare providers to improve patient outcomes.

TeselaGen’s artificial intelligence-enabled operating system for designing, building, and optimizing bio-based products is driving innovation across the biotechnology sector.